Your browser doesn't support javascript.
loading
lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma.
Wang, Qiang; Xiao, GuangJun; Li, Na; Jiang, Xiulin; Li, Chunhong.
Affiliation
  • Wang Q; Gastrointestinal Surgical Unit, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.
  • Xiao G; Department of Clinical Laboratory Medicine, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.
  • Li N; Department of Oncology, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.
  • Jiang X; Department of Oncology, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.
  • Li C; Department of Oncology, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.
Aging (Albany NY) ; 15(10): 4510-4523, 2023 05 31.
Article in En | MEDLINE | ID: mdl-37256932
Integrin alpha L (ITGAL) seemed to play a critical role in carcinogenesis and immune regulation. Nevertheless, the effects of ITGAL on non-small cell lung cancer (NSCLC) remain elusive. The present paper intended to determine the effects of ITGAL in NSCLC via the integration of bioinformatic analyses. In this study, we found that the mRNA and protein levels of ITGAL were downregulated in NSCLC tissues. Significantly, low ITGAL expression was related to poorer prognosis and increased malignancy of NSCLC. In addition, GO analysis and KEGG pathway analysis revealed that the coexpressed genes of ITGAL were predominantly associated with various immune-associated signaling pathways, like the T cell receptor signaling pathway, Th17 cell differentiation, chemokine signaling pathway, and NF-κB signaling pathway. Our result indicated that lncRNA-mediated downregulation of integrin alpha L expression was tightly related to immunocyte infiltration, immune modulators, and chemotactic factors in NSCLC, which potentially serves as a biomarker for clinical prognosis prediction and immunotherapy of NSCLC. This is the first comprehensive analysis of ITGAL in the prognosis, immune microenvironment, and immunotherapy of lung adenocarcinoma. ITGAL are promising biomarkers for predicting clinical outcomes and immunotherapy responses in patients with NSCLC.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Carcinoma, Non-Small-Cell Lung / RNA, Long Noncoding / Lung Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Aging (Albany NY) Journal subject: GERIATRIA Year: 2023 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Carcinoma, Non-Small-Cell Lung / RNA, Long Noncoding / Lung Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Aging (Albany NY) Journal subject: GERIATRIA Year: 2023 Document type: Article Country of publication: United States